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The effects of quinidine on steady state serum and tissue
digoxin concentrations in the neonatal dog were studied.
To determine the effects of quinidine on serum digoxin
concentrations, two groups of neonates were evaluated:
Group I (n = 11) was digitalized with 40 ILg/kg body
weight, intramuscularly, and placed on a io ILg/kg per
day maintenance dose; Group II (n = 7) was digitalized
with 50 ILg/kg per day, iniraperitoneally, and placed on
a 20 ILg/kg per day maintenance dose. After 10 days of
digoxin alone, quinidine was coadministered (30 mg/kg
per day, intraperitoneally) for 7 days. Serum digoxin
concentrations were measured before quinidine and 1,
3 and 7 days after combined digoxin-quinidine therapy.
In Group I, the control serum digoxin concentration was
1.38 ± 0.32 ng/inl and after 7 days of combined therapy
it was unchanged (1.39 ± 0.31 ng/ml). In Group II, the
control serum digoxin concentration measured 2.80 ±
0.49 ng/ml and after 7 days of combined therapy it, too,
was unchanged (3.10 ± 0.65 ng/ml).
The effects of combined digoxin-quinidine adminis-
tration on tissue digoxin concentrations were studied in
two other groups of neonates. Group III (n = 6) was
It has become increasingly apparent that a number of phar-
macologic agents can alter the pharmacokinetics of digoxin
and result in increased serum digoxin concentrations (1-3).
The interaction between digoxin and quinidine was the first
of such interactions to be recognized and, since the first
description in 1978 (4), has been studied extensively both
in the clinical setting and in the animal laboratory (5-13).
The salient features of the interaction (9) are that quinidine
adminstration results in an increase in the serum digoxin
concentration as early as a few hours after the first dose of
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given a low maintenance dose of digoxin (10 ILg/kg per
day,intramuscularly) and a full 7 days of coadministered
quinidine; in Group IV (n = 6), digoxin was given at a
higher dose (20 ILg/kg per day, intraperitoneally) and a
shorter duration of combined digoxin-quinidine therapy
(3 days). Tissue samples of skeletal muscle, brain, myo-
cardium, liver and kidney were analyzed for digoxin
content and compared with tissue levels measured in
control neonates given digoxin alone. Brain digoxin con-
centrations were higher in Group IV (910 ± 437 ng/g)
compared with neonates given digoxin alone (530 ± 49
ng/g). In both Groups III and IV, digoxin tissue con-
centrations in skeletal muscle, liver and brain, normal-
ized for the serum digoxin level, were significantlyhigher
than in control neonates.
In the neonatal dog, quinidine administration results
in little or no increase in the steady state serum digoxin
concentration. However, quinidine may be associated
with higher brain digoxin levels, particularly at higher
digoxin doses and serum levels.
(J Am Coil CardioI1986;8:669-74)
quinidine, usually peaking in a few days. There is often a
two- to threefold serum digoxin increase. The interaction
appears to be independent of the serum digoxin concentra-
tion and occurs even in the presence of low serum quinidine
concentrations. It has been hypothesized that quinidine may
alter the renal clearance of digoxin by suppressing digoxin
renal tubular secretion (9,14).
We have previously reported (15) that in the neonatal
dog, no increases in serum digoxin concentrations are ob-
served after 3 days of combined intraperitoneal digoxin and
quinidine therapy. Furthermore, Koren (3) has recently re-
ported that although quinidine results in a significant in-
crease in the serum digoxin concentration in children over
the age of 5 years, no increases were observed in any of
three infants studied at less than 2 months of age. These
data suggest that the digoxin-quinidirie interaction in the
immature human or animal may be qualitatively different
from that observed in the adult.
The objectives ofthis study were to: 1) quantitate changes
in steady state serum digoxin concentrations in the neonatal
0735-1097/86/$3.50
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puppy given combined digoxin-quinidine therapy over an
extended period of time (7 days) and over a range of serum
digoxin concentrations; and 2) to document changes in tissue
digoxin concentrations in neonatal puppies given combined
digoxin-quinidine therapy.
Methods
For both the serum and tissue studies, the experimental
subjects were neonatal mongrel puppies. All puppies were
digitalized at 10 days of age and placed on 10 days of
maintenance digoxin therapy before beginning quinidine
therapy. In all studies, maintenance digoxin doses were
administered at approximately 5 PM and blood samples for
digoxin serum concentrations were obtained at approxi-
mately 10 AM (during the elimination phase). Specific pro-
tocols for each experiment are described.
Serum digoxin studies (Groups I and II). To quantitate
the effects of combined digoxin-quinidine administration on
steady state serum digoxin concentrations, two groups of
neonates were studied. Group I consisted of II neonates
that were digitalized with 40 jLg/kg body weight, intra-
muscularly, and subsequently placed on daily maintenance
digoxin doses of 10 jLg/kg per day, given intramuscularly
at rotating sites. Quinidine sulfate was begun after 10 days
of maintenance digoxin therapy at a dose of 15 mg/kg twice
a day, intraperitoneally.
To study neonates with higher serum digoxin concentra-
tions, as well as to assess the influence ofthe route of digoxin
adminstration on any observed interaction, a second group
of neonates was studied (Group II). These neonates (n =
7) were studied in an identical fashion except that digoxin
was given intraperitoneally as a 50 jLg/kg digitalization dose
and a 20 jLg/kg per day maintenance dose.
In both Groups I and II, serum digoxin concentrations
were measured by radioimmunoassay (Coat-A-Count, Di-
agnostic Products Corp.) before giving quinidine and 1, 3
and 7 days after starting quinidine. The possibility of dig-
oxin-like substances (16) being detected with this radioim-
munoassay was excluded by analyzing serum samples of
many of the neonates reported here (and of other neonatal
dogs) before digoxin adminstration. These levels were con-
sistently O. Quinidine levels were also determined and mea-
sured by gas-liquid chromatography (17).
Statistical analysis of the effects of quinidine on mean
serum digoxin concentration was assessed by analysis of
variance. A probability (p) value of less than 0.05 was
required to indicate statistical significance.
Tissue studies (Groups III and IV). In the second part
of the study, digoxin tissue concentrations were measured
in groups of neonates receiving digoxin and quinidine and
compared with values obtained in neonates given digoxin
alone. Two digoxin-dosing protocols were utilized. In the
first group (Group III, n = 6), digoxin and quinidine were
coadministered for a total of 7 days. Digoxin was admin-
istered intramuscularly at a dose of 10 jLg/kg per day. In
the second tissue group (Group IV, n = 6), digoxin was
given at a higher maintenance dose (20 jLg/kg per day) and
was administered intraperitoneally. Digoxin and quinidine
were coadministered for 3 days.
At the conclusion of the dosing protocols, samples of
heart, skeletal muscle, brain, kidney and liver were taken
from each of the experimental subjects for analysis of dig-
oxin concentration. Tissue samples were also obtained from
groups of control neonates that had received digoxin by the
same dosage protocols as Groups III and IV, but without
the addition of quinidine. The control neonates for Group
III consisted of seven dogs treated with digoxin alone, and
the control neonates for Group IV consisted of eight dogs
treated with digoxin alone.
All tissue samples were obtained rapidly after death was
induced (pentobarbital anesthesia followed by potassium
chloride), and were freed of all visible fat and connective
tissue. Samples were then lyophylizedfor 24 hours at - 70°C.
The freeze-dried tissues were then cleaned of remaining fat
and connective tissue and weighed. Digoxin was extracted
from the tissue by first shaking the samples in 2 cc of 0.02
M phosphate buffer and then adding 5 cc of dichlorometh-
ane. The dichloromethane layer was collected (above pro-
cedure repeated twice) and evaporated in a water bath at
50°C until dry. After drying, the residue was resuspended
in 0.5 cc of digoxin-free human serum and assayed by
radioimmunoassay. Extraction efficiencies were determined
by adding 0.1 cc of 8 ng/ml of digoxin standard to digoxin-
free canine heart tissue and assaying these samples in each
extraction procedure. Extraction efficiencies ranged from
75 to 100%; all radioimmunoassay determinations (serum
and tissue) were performed in duplicate and percent coef-
ficients of variance of less than 10 were considered ac-
ceptable. A detailed description of this method of tissue
analysis has been previously described (18).
Statistics. Statistical comparisons of tissue digoxin con-
centrations (expressed both as an absolute value in nano-
grams per gram dry weight and as a ratio to the serum
digoxin concentration in milliliters per gram) were made
between the digoxin-quinidine and control group neonates
utilizing a standard t test. A p value of less than 0.05 was
required to indicate significance.
Results
Serum digoxin studies. The serum digoxin determi-
nations (and corresponding quinidine levels) before and dur-
ing the 7 days of combined digoxin-quinidine therapy are
presented for Groups I and II in Table 1. In Group I (low
dose digoxin), the control serum digoxin concentration, after
10 days of maintenance digoxin, measured 1.38 :±: 0.32
(mean:±: SD). After a full 7 days of coadministered quin-
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Table 1. Digoxin-Quinidine Interaction in the Neonate
Days After Quinidine
Control 3 7
Group I (n = II)
Digoxin (ng/ml) 1.38 ± 0.32 1.43 ± 0.23 1.71 ± 0.30* 1.39 ± 0.31
Quinidine (mg/liter) 4.25 ± 0.86 4.35 ± 1.12 3.58 ± 0.54
Group II (n = 7)
Digoxin (ng/ml) 2.80 ± 0.49 2.60 ± 0.48 2.60 ± 0.53 3.10 ± 0.65
Quinidine (mg/liter) 4.10 ± 1.00 2.70 ± 1.47 3.70 ± 1.67
*p < 0.03. Data are reported as mean ± SO. n = number of subjects.
idine, and despite achievement of adequate serum quinidine
concentrations during the entire period of time, the serum
digoxin concentration remained unchanged, measuring
1.39 ± 0.31 ng/ml (Fig. 1). After 3 days of combined
digoxin-quinidine adminstration, a small mean increase of
0.30 ng/rnl in the serum digoxin concentration was ob-
served. This small increase results in a significant p value
(0.03) for the overall relation by analysis of variance. How-
ever, apart from the very modest (and unsustained) increase
at day 3, no apparent overall increase was observed in the
serum digoxin concentrations in this group of neonates after
the addition of quinidine.
In Group Il, the control serum digoxin concentration
measured 2.80 ± 0.49 ng/ml (Fig. 2). No increases were
observed in the serum digoxin concentration over the entire
7 days of combined digoxin-quinidine therapy (serum dig-
oxin concentration 3.10 ± 0.65 ng/ml after 7 days of com-
bined therapy). Again, serum quinidine concentrations
achieved during this period of combined therapy were all
well above the value of 1.9 mg/liter, thought to be the
threshold quinidine concentration at which the interaction
between digoxin and quinidine is observed (19). Thus in
both neonate Groups I and II, no significant quinidine-re-
lated rise in the serum digoxin concentration could be dem-
onstrated after 1 week of combined therapy.
Tissue digoxin studies. Tissue digoxin concentrations
and tissue digoxin concentrations normalized for serum dig-
oxin concentration (tissue/serum ratio) for Group III are
presented in Table 2A. For comparison, digoxin tissue levels
obtained from a group of seven neonates treated identically
to Group III except for the omission of quinidine are also
presented. At the time of tissue collection, the serum digoxin
concentration in the digoxin-quinidine group was 1.19 ±
0.13 ng/ml and in the control group was 2.00 ± 0.28 ng/m!.
Inspection of the absolute digoxin tissue levels reveals
no significant differences between the digoxin-quinidine and
digoxin alone groups in brain, heart, kidney, liver or skeletal
muscle digoxin concentrations. However, when the data are
normalized for the attained serum digoxin concentration
(tissue/serum ratio) a significantly higher normalized dig-
oxin tissue concentration is observed in the digoxin-quini-
dine neonates for the brain (254 ± 70 versus 156 ± 42
mllg) , liver (112 ± 13 versus 72 ± 10 mllg) and skeletal
muscle (180 ± 11 versus 108 ± 24 mllg) (Fig. 3). Thus,
despite attainment of a lower serum digoxin concentration
in the neonates receiving digoxin plus quinidine, tissue
Figure 1. Group I serum digoxin (D) determinations before (C)
administering quinidine (Q) and I, 3 and 7 days after adding
quinidine. 1M = intramuscular; IP = intraperitoneal.
Figure 2. Group II serum digoxin determinations before (C) and
I, 3 and 7 days after adding quinidine. Abbreviations as in Fig-
ure 1.
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Table 2. Digoxin-Quinidine Interaction in the Neonate Tissue Study
Digoxin Tissue Level
(ng/g dry weight)"
Tissue/Serum Ratio
(mllg)*
D.Q D D,Q D
A. Group III (D.Q) Versus Control (D)
Brain 306 :t 104 304 :t 61 254 :t 70t 156 ± 42
Heart 374 :t 82 537 :t 178 315 ± 73 272 ± 89
Kidney 1,796 :t 469 2.125 :t 457 1.524 ± 473 1.065 :t 185
Liver 134 :t 25 142 :t 16 11 2 ± 13t 72 ± 10
Skeletal muscle 130 :t 35 156 :t 28 180 :t I It 108 ± 24
B. Group IV (O.Q) Versus Control (0 )
Brain 910 :± 437t 530 :± 49 229 :± 106t 100 :t 20
Heart 892 ± 167 991 ± 112 222 ± 33t 185 :± 18
Kidney 5,179 :± 465 4.634 ± 1,220 1,297 :± 163t 873 ± 241
Liver 368 :t 86 356 :± 89 93 ± 28t 66 :± I I
Skeletal muscle 267 :± 40 248 :± 46 67 ± 14t 46 :± 9
*Mean :t SO; t p < 0.05, I test comparison of tissue/serum ratio. D = digoxin; Q = quinidine.
levels in this group were comparable with those observed
in the control group. When normali zed for the serum digoxin
level, relatively higher tissue digoxi n concentrations were
observed in liver, muscle and brain.
Tissue concentrations and corrected digoxin tissue con-
centrationsfor Group IV are presented in Table 28 . Again,
for comparison , digoxin tissue levels obtained from a group
of neonates (n = 8) treated identically excep t without quin-
idine are shown. As in Group III , the attained serum digoxin
conce ntratio n in the digoxin-quinidine grou p was lower than
that measured in the control group (4 .03 ± 0.47 versus
5.4 1 ± 0 .77 ng/ml) (p < 0.002) . Abso lute tissue digoxin
concentrations in the digoxin-quinidine and control neonates
were not significantly differe nt for heart , kidney, liver or
skeletal muscle. However, in the digoxin-quinidine-treated
neonates, a significantly higher brain digoxin concentration
was measured (9 10 ± 437 versus 530 ± 49 ng/g) (p <
0.03) (Fig . 4). Inspection of the graph shows that five of
the six neonates had a greater brain digoxin concentration
than all of the values measured in the contro l (digoxi n only)
group.
When normalized fo r the serum digoxin concentration,
tissue concentrations (tissue/serum ratio) were significantly
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Figure 3. Brain digoxin (D) concen trations normalized for serum
digoxin level are plotted for Group III neonates (digoxin and quin-
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only) on the left . A higher digoxin tissue to serum ratio is observed
in the neonates receiving combined digoxin-quinidi ne (Q) therapy.
Similar findings were observed for liver and skeletal muscle in
these groups. Abbreviations as in Figure I .
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Figure 5. Brain digoxin (D) concentrations, normalized for serum
digoxin level, are plotted for Group IV neonates on the right and
control neonates on the left, A higher digoxin tissue to serum ratio
is observed in the neonates receiving combined digoxin-quinidine
therapy. Abbreviations as in Figure 1.
higher in the digoxin-quinidine group not only in the brain
(Fig. 5) but in all of the other tissue sites as well (Table
2B).
Discussion
Previous studies in the adult dog have clearly demon-
strated that, as in the adult human, the administration of
quinidine can result in a substantial increase in the steady
state serum digoxin concentration (10,11,13,20). Increases
in the serum digoxin concentrationhave been observed within
days of beginning quinidine therapy and have been observed
utilizing drug-dosing protocols employing intravenous
(11,13), oral (10) or combined (20) methods of drug ad-
minstration. The magnitude of the increases in serum dig-
oxin concentration has been variable, but increases as high
as 100% (doubling of the serum digoxin concentration) are
commonly reported. Pharmacokinetic studies in the dog (20)
have suggested that the increase in the serum digoxin con-
centration may, at least in part, be due to a quinidine-
mediated reduction in the clearance of digoxin. Thus, it
seems that the adult dog provides a suitable animal model
for studying the digoxin-quinidine interaction, exhibiting
essentially the same pharmacokinetic characteristics of the
drug interaction as described in the adult human.
Effects of quinidine on serum digoxin concentration.
The major finding of our study is that over at least 7 days
of coadministration, quinidine results in little or no appre-
ciable increases in the serum digoxin concentration in the
neonatal dog. Despite achieving adequate digoxin and quin-
idine serum concentrationsand examining two different routes
of administration (intramuscular and intraperitoneal), we
were unable to demonstrate a quinidine-mediated increase
in the serum digoxin concentration in the neonate. The re-
sults of this investigation, as well as the recent clinical
observations by Koren (3) in which no increases were ob-
served in the serum digoxin concentration of three infant
humans given combined digoxin-quinidine therapy, raise
the important question of whether there is a lack of an
interaction in the neonate or whether, in fact, the interaction
occurs and is quantitatively or qualitatively different from
that described in the adult. Considering the multitude of
differences known to exist in drug distribution, protein bind-
ing, metabolism and excretion in the neonate (21,22), it is
not at all improbable that drug interactions in the neonate
may also be quite different.
Effects of quinidine on tissue digoxin concentrations.
We believe that the question of whether a digoxin-quinidine
interaction occurs in the neonatal dog is best answered by
considering the results of the tissue digoxin analyses. In
examining the tissue digoxin data, it is first necessary to
appreciate that previous studies in adult dogs have reported
somewhat variable findings. Doherty et al. (11) compared
the tissue digoxin concentrations in dogs given 4 days of
digoxin alone and in dogs given 3 days of coadministered
quinidine. They reported a significant increase in the brain
digoxin concentration (51%) in the digoxin-quinidine group
in association with significantly lower digoxin concentra-
tions in left and right ventricular myocardium (20%), kidney
(27%) and skeletal muscle (30%). When the tissue/serum
ratios were analyzed, in addition to a significant increase in
the brain digoxin concentration, a significant decrease in
skeletal muscle digoxin concentration was again calculated.
Doherty et al. concluded that quinidine may have resulted
in a displacement of digoxin from certain tissue sites (spe-
cifically skeletal muscle) to the brain and pointed out the
potential role of an increased brain digoxin concentration
in mediating digoxin intoxication.
Warner et al. (13) recently reported the results of digoxin
tissue analyses in dogs receiving digoxin alone and in dogs
given 4 to 7 days of digoxin with quinidine. In contrast to
the previous study, higher tissue digoxin concentrations were
measured in myocardium, liver, kidney and skeletal muscle
in dogs treated with digoxin and quinidine. These investi-
gators also found a significantly increased digoxin concen-
tration in the cerebral gray matter, cerebellum and pons but
concluded, based on analysis of the tissue/serum ratio, that
the increased brain digoxin concentrations (as well as myo-
cardium, liver, kidney and skeletal muscle concentrations)
were explained by the increased serum digoxin concentra-
tions achieved in the digoxin-quinidine group.
In our tissue studies, neonates given high doses of dig-
oxin (20 jLg/kg per day) and 3 days of combined digoxin-
quinidine therapy had a significantly higher brain digoxin
concentration than that found in neonates given digoxin
alone (Table 2B, Fig. 4). This increased brain digoxin con-
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centration was observed despite achievement of serum dig-
oxin concentrations that were actually lower in the digoxin-
quinidine group. As a result of the lower serum digoxin
concentration. tissue /serum ratios of not only brain but also
heart , kidney, liver and skeletal muscle were significantly
higher in the digoxin-quinidine-treated neonates. Similarly,
although no significant differences were observed in the
tissue concentrations of neonates given 7 days of low dose
digoxin (10 p.g/kg per day) plus quinidine and those given
digoxin alone, the tissue/serum ratios of brain, liver and
skeletal muscle were significantly higher in the digoxin-
quinidine group than in the neonates receiving only digoxin;
this is because of the lower serum digoxin concentrations
achieved in the digoxin-quinidine group.
Thus. despite the inability to show a significant change
in the serum digoxin concentration in neonates given com-
bined digoxin and quinidine, the tissue data are strongly
suggestive of an interaction in which relatively higher tissue
digoxin concentrations are achieved, particularly in the brain,
iri neonates given combined digoxin-quinidine therapy . The
exact mechanisms by which quinidine results in a relative
or absolute increase in the digoxin concentration of the brain
despite little or no increase in serum digoxin concentration
cannot be determined from our study. Nevertheless, our data
are concordant with the observations of Doherty et al. (II),
who also observed increased brain digoxin concentrations
with no apparent increases in the serum digoxin concentra-
tion . More detailed pharmacokinetic studies , including stud-
ies looking for transient shifts in digoxin tissue content (as
hypothesized by Doherty et al. [II]) as well as studies
investigating specific tissue-binding characteristics of dig-
oxin with and without quinidine, would be required to fully
describe and characterize the neonatal digoxin-quinidine in-
teraction .
Conclusions. This study demonstrates that in the neo-
natal dog, little or no increase in the serum digoxin con-
centration is observed during combined digoxin-quinidine
therapy . Nevertheless, quinidine administration may result
in higher digoxin concentrations in the brain (as weIl as
other tissue sites) , particularly at higher serum digoxin lev-
els . Because higher brain digoxin concentrations may be
important in mediating the clinical manifestations of digoxin
intoxication , caution is still indicated when digoxin and
quinidine are utilized together in the neonatal period .
We thank Diane McMullen for excellent secretarial assistance and Albert
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